Point Biopharma

About

Point Biopharma is a wholly owned subsidiary of Eli Lilly and Company, specializing as a multinational radiopharmaceutical company engaged in the development and commercialization of radioligand therapies for cancer patients. The Indianapolis facility is licensed for alpha and beta-emitting isotopes and contains dedicated space for commercial-scale automated packaging. Located at the Crossroads of America, shipments from the facility can reach 50% of the US population within 10 hours by ground transportation.